BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter - 2Zelensky sees new Russian attack threat from Belarus
- 3UNICEF: More than 100 children killed in Gaza since ceasefire
- 4Flu season is ramping up, and some experts are "pretty worried"
- 5Israel kidnaps PIJ terrorist in covert op. in Hamas-controlled Gaza in pursuit of Ran Gvili
- Woman gives birth on roadside after hospital allegedly sent her home: Family
- Home Plan Tips for Seniors
- German foreign minister heads to China to talk rare-earth exports
- 6 Shades Brands For Seniors
- Mickey Lee of 'Big Brother' fame dead at 35 after flu complications, family says
- Benin coup thwarted by loyalist troops, president tells nation
- Vote in favor of Your Number one BWM Vehicles
- How grandchildren are stepping up to fill the caregiver gap
- Find the Mysteries of Powerful Using time productively: Augmenting Efficiency and Proficiency
